

*Investor Relations Department (IR)
 Imexpharm Corporation
 Add : 63B-65B No.2 Street, Lu Gia Block, Ward 15, District 11, HCMC.
 Tel : (+84.28) 3866.9856
 Email : ir@imexpharm.com*

Imexpharm Investor Relations News August, 2022


I. REPORT ON BUSINESS AND PRODUCTION RESULTS IN AUGUST 2022

Criteria	August 2022	YTD August 2022	31 %Planned 2022	YTD August 2021	31 Growth rate
Total net revenue and other incomes	146.0	954.2	65.8%	793.9	20.2%
Net revenue	145.6	939.3		779.3	20.5%
Profit before tax	25.1	171.4	62.3%	144.9	18.3%

Imexpharm's total net revenue and other incomes in the first 8 months of 2022 reached VND 954.2 billion, increased 20.2% over the same period, and made up 65.8% of the annual plan. Imexpharm mainly distributes products manufactured by the Company, which account for 97.6% of total net revenue whereas franchising products and other purchases made up about 2.4%.

Meanwhile, IMP's pre-tax profit in the first 8 months of 2022 attained VND 171.4 billion, which is meeting 62.3% of the annual plan set by the General Meeting of Shareholders and grew by 18.3% year over year. The growth rate of accumulated profit in the first 8 months of 2022 was lower than the net revenue's figure. The reason behind this issue mainly came from the increased in administrative expenses grew by 47% over the same period because of the rise in basic salary along with influenced of fuel price and other commodity in Q2 and in August 2021, the southern provinces were implementing social distancing, so the company did not incur many management costs. Besides, Imexpharm has well controlled cost of goods sold. Also in the first eight months of 2022, COGS increased by 18% year over year in the context that global supply chains are still broken and prices are escalating due to inflation, and selling expenses went up by 20% year over year. In addition, IMP's gross profit margin was 42.3% and slightly higher than 41% for the same period in 2021.

Imexpharm's OTC channel in 8 months has impressive growth of 41.7%. Meanwhile, ETC has recovered but still has negative growth of 2.1%. Vietnam's healthcare market is growing rapidly. Accordingly, modern retail businesses are constantly accelerating the race in the market, helping OTC channel revenue to maintain a strong growth momentum. In addition, the hospital channel has recovered after a limited period of accepting patients to carry out the prevention of the Covid-19 pandemic, bringing stable growth to the ETC channel.



II. IMP STOCK IN AUGUST 2022

Through 23 trading sessions in August, total order-matching amounts were 46,200 shares and there was no put-through transaction. In comparison with the volume of 426,000 shares in August 2021, the transaction in August 2022 is only 10%.

In August 2022, Imexpharm Corporation has received dossiers for public offer from the related party of Mr. Truong Minh Hung – Member of the Board of Directors, being SK Investment Vina III Pte.Ltd, to raise the ownership ratio of SK and related parties at Imexpharm. SK Investment registered for public offer to acquire 733,759 shares at the price of VND 66,000/share, equivalent to 1.1% of the Charter Capital, to raise the ownership rate from 53.94% to 55.04%.

III. REMARKABLE ACTIVITIES IN AUGUST 2022 AND PLANS FOR SEPTEMBER 2022

In August, Imexpharm closely followed markets and customers, promoted sales programs to boost sales in the last six months of 2022. Besides, IMP also actively controlled, monitored and recovered debts.

In September 2022, Imexpharm will continue to implement sales support programs to achieve revenue and profit goals set by the General Meeting of Shareholders, as well as to control debts and inventories to shorten the operating cycle. At the same time, IMP also closely monitors the raw material price fluctuations to have appropriate hoarding policies, contributing to stabilizing prices and profit margins.